Cambiar Investors LLC Sells 5,880 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Cambiar Investors LLC lowered its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 12.8% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 40,050 shares of the medical research company’s stock after selling 5,880 shares during the period. Cambiar Investors LLC owned approximately 0.08% of Charles River Laboratories International worth $7,393,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. North Growth Management Ltd. lifted its holdings in shares of Charles River Laboratories International by 18.2% during the 4th quarter. North Growth Management Ltd. now owns 39,000 shares of the medical research company’s stock worth $7,168,000 after acquiring an additional 6,000 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd lifted its holdings in shares of Charles River Laboratories International by 2.3% during the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 5,951 shares of the medical research company’s stock worth $1,099,000 after acquiring an additional 133 shares during the period. Sumitomo Mitsui Trust Group Inc. lifted its holdings in shares of Charles River Laboratories International by 11.7% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 125,097 shares of the medical research company’s stock worth $23,093,000 after acquiring an additional 13,102 shares during the period. YANKCOM Partnership bought a new stake in shares of Charles River Laboratories International during the 4th quarter worth approximately $92,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Charles River Laboratories International by 46.4% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,301 shares of the medical research company’s stock worth $987,000 after acquiring an additional 1,679 shares during the period. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Trading Down 2.4 %

Shares of NYSE CRL opened at $159.90 on Tuesday. Charles River Laboratories International, Inc. has a 52-week low of $157.41 and a 52-week high of $275.00. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48. The firm has a 50 day moving average price of $179.79 and a two-hundred day moving average price of $192.80. The stock has a market cap of $8.18 billion, a P/E ratio of 20.01, a price-to-earnings-growth ratio of 6.47 and a beta of 1.37.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on CRL. Bank of America cut their price target on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a report on Friday, December 13th. StockNews.com cut shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Thursday, November 7th. CLSA cut shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price objective for the company. in a research report on Monday, November 18th. William Blair cut shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 22nd. Finally, Morgan Stanley lowered their price objective on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 5th. Three analysts have rated the stock with a sell rating, fourteen have given a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $200.79.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).